PolyPid Ltd. (PYPD) stock
PYPDNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
$6.26−0.14 (-2.19%)
Close on Nov 13, 2026Market cap $113.96MP/E 3.0Yield –
PolyPid EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
For fiscal 2025 it was $2.09, down 57.4% from the year before. The highest annual figure on record is $710.70 in fiscal 2019.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.09 | -57.4% |
| FY2024 | Dec 31, 2024 | $4.91 | -71.0% |
| FY2023 | Dec 31, 2023 | $16.93 | -72.3% |
| FY2022 | Dec 31, 2022 | $61.09 | -10.5% |
| FY2021 | Dec 31, 2021 | $68.27 | -49.2% |
| FY2020 | Dec 31, 2020 | $134.40 | -81.1% |
| FY2019 | Dec 31, 2019 | $710.70 | +2654.7% |
| FY2018 | Dec 31, 2018 | $25.80 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2025 | Jun 30, 2025 | $0.78 | -95.4% |
| Q2 FY2024 | Jun 30, 2024 | $1.25 | -99.8% |
| Q2 FY2023 | Jun 30, 2023 | $3.95 | – |
| Q2 FY2022 | Jun 30, 2022 | $18.30 | – |
| Q2 FY2021 | Jun 30, 2021 | $16.80 | – |
| Q2 FY2020 | Jun 30, 2020 | $759.00 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?